The use of intravesical oxybutynin chloride in children with neurogenic bladder

J Urol. 1991 Aug;146(2 ( Pt 2)):532-4. doi: 10.1016/s0022-5347(17)37845-x.

Abstract

Intravesical oxybutynin chloride was administered to 10 children with neurogenic bladder (myelomeningocele in 9 and imperforate anus in 1) and urinary incontinence refractory to regimens of intermittent catheterization and oral anticholinergic medication. Therapy consisted of instillation of 5 mg. crushed oxybutynin chloride in 10 cc sterile saline twice daily. Of the children 5 (50%) became completely dry day and night, 3 (30%) achieved daytime continence alone, and 2 did not improve clinically and remained in diapers. Urodynamic study revealed increases in bladder capacity up to 335% over baseline and decreases of maximum filling pressures to 63%. No local or systemic side effects were noted. Surgical bladder augmentation was avoided in those who clinically responded to this therapy.

MeSH terms

  • Administration, Intravesical
  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Mandelic Acids / administration & dosage
  • Mandelic Acids / therapeutic use*
  • Parasympatholytics / administration & dosage
  • Parasympatholytics / therapeutic use
  • Urinary Bladder, Neurogenic / complications
  • Urinary Bladder, Neurogenic / drug therapy*
  • Urinary Bladder, Neurogenic / physiopathology
  • Urinary Incontinence / drug therapy*
  • Urinary Incontinence / etiology
  • Urinary Incontinence / physiopathology
  • Urodynamics

Substances

  • Mandelic Acids
  • Parasympatholytics
  • oxybutynin